Welcome to LookChem.com Sign In|Join Free
  • or
4-chloro-N-(1-methyl-1H-pyrazol-5-yl)benzenesulfonamide is a chemical compound with the molecular formula C11H11ClN3O2S. It is a derivative of benzenesulfonamide, featuring a chloro substituent at the 4-position and a 1-methyl-1H-pyrazol-5-yl group attached to the nitrogen atom. 4-chloro-N-(1-methyl-1H-pyrazol-5-yl)benzenesulfonamide is known for its potential applications in pharmaceuticals and agrochemicals, particularly as a building block for the synthesis of various active ingredients. Its structure allows for the exploration of its properties and reactivity, which can be crucial in the development of new drugs or pesticides. The compound's specific role in these fields is determined by its ability to interact with biological targets, such as enzymes or receptors, which can lead to therapeutic or pesticidal effects.

5064-26-6

Post Buying Request

5064-26-6 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

5064-26-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 5064-26-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,0,6 and 4 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 5064-26:
(6*5)+(5*0)+(4*6)+(3*4)+(2*2)+(1*6)=76
76 % 10 = 6
So 5064-26-6 is a valid CAS Registry Number.

5064-26-6Downstream Products

5064-26-6Relevant academic research and scientific papers

Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists

Katte, Timothy A.,Reekie, Tristan A.,Werry, Eryn L.,Jorgensen, William T.,Boyd, Rochelle,Wong, Erick C.N.,Gulliver, Damien W.,Connor, Mark,Kassiou, Michael

, p. 330 - 333 (2017)

The neuropeptide oxytocin has been implicated in multiple central nervous system functions in mammalian species. Increased levels have been reported to improve trust, alleviate symptoms related to autism and social phobias, and reduce social anxiety. Hoffman-La Roche published a patent claiming to have found potent small molecule oxytocin receptor agonists, smaller than the first non-peptide oxytocin agonist reported, WAY 267,464. We selected two of the more potent compounds from the patent and, in addition, created WAY 267,464 hybrid structures and determined their oxytocin and vasopressin receptor activity. Human embryonic kidney and Chinese hamster ovary cells were used for the expression of oxytocin or vasopressin 1a receptors and activity assessed via IP1 accumulation assays and calcium FLIPR assays. The results concluded that the reported compounds in the patent and the hybrid structures have no activity at the oxytocin or vasopressin 1a receptors.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 5064-26-6